Granules India is currently trading at Rs. 288.30, up by 2.75 points or 0.96% from its previous closing of Rs. 285.55 on the BSE.
The scrip opened at Rs. 285.75 and has touched a high and low of Rs. 289.00 and Rs. 285.75 respectively. So far 38097 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 289.00 and Rs. 275.30 respectively. The current market cap of the company is Rs. 6986.56 crore.
The promoters holding in the company stood at 42.02%, while Institutions and Non-Institutions held 28.93% and 29.05% respectively.
Granules India has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets USP, 250 mg, 500 mg, 750 mg, and 1,000 mg. bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Keppra Tablets of UCB, Inc. (UCB).
Levetiracetam Tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and infants of age 1 month and older children with epilepsy; Myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy; Primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.
Granules now has a total of 58 ANDA approvals from USFDA (56 Final approvals and 2 tentative approvals).The current annual U.S. market for Levetiracetam Tablets is around $247 million, according to MAT March 2023, IQVIA/IMS Health.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1861.70 |
| Dr. Reddys Lab | 1389.35 |
| Cipla | 1506.15 |
| Lupin | 2228.00 |
| Zydus Lifesciences | 972.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
